Abstract:
Metabolic syndrome represents a set of interrelated disorders, such as insulin
resistance, hypertension, dyslipidemia, and central obesity, which significantly
increase the risk of cardiovascular diseases and type 2 diabetes. In recent years, the
use of semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a new
therapeutic approach capable of promoting weight reduction and improving glycemic
control. This study aimed to analyze the risks and benefits of semaglutide in the
treatment of metabolic syndrome, emphasizing its therapeutic efficacy and potentialadverse effects. This is a literature review conducted through the analysis of recent
scientific articles available in national and international databases. The results showed
that semaglutide promotes significant weight loss, improvement in cardiometabolic
parameters, and good tolerability, although some gastrointestinal effects, such as
nausea, vomiting, diarrhea, and constipation, are frequently reported. It is concluded
that the drug represents an important advance in the treatment of metabolic diseases,
provided that it is used rationally, with multiprofessional monitoring and expanded
access policies. Further studies are needed to evaluate its long-term effects and
optimize its clinical use.
